ArticleOncoimmunology2020

Doxorubicin pretreatment enhances FAPα/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model.

Fei Geng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.